BACKGROUND: Plerixafor (Mozobil, AMD3100) with granulocyte-colony stimulating factor (G-CSF) mobilizes more CD34+ cells/kg compared to G-CSF alone. Given that plerixafor enhances mobilization of multiple white blood cell lineages, we determined if more storage space is required for products collected from patients mobilized with plerixafor. METHODS: A review of the medical records of 15 patients mobilized with chemotherapy and G-CSF (control) and 14 patients mobilized with plerixafor plus G-CSF (plerixafor) was performed. Data on demographics, baseline characteristics, CD34+ cells/kg, total nucleated cells, total mononuclear cells, total apheresis sessions, and total bags for storage were collected. Mean values were determined and compared using Student's t-test. RESULTS: We found that the proportion of CD34+ cells among total nucleated cells was less in the plerixafor group compared to the control group (P = 0.0427). More nucleated cells (10.7 x 10(10) vs. 7.1 x 10(10), P =0.0452) and mononuclear cells (9.7 x 10(10) vs. 5.9 x 10(10), P = 0.0059) were mobilized with plerixafor plus G-CSF. However, there was no significant difference in CD34+ cells/kg, total CD34+ cells or the proportion of mononuclear cells among total nucleated cells between the two groups. More storage bags were required for the plerixafor group compared to the control group (15 vs. 9, P = 0.0299). CONCLUSION: Mobilization with plerixafor plus G-CSF resulted in a smaller proportion of CD34+ cells collected and a greater number of storage bags. An increase in the number of bags required for stem cell storage may be logistically problematic and will also lead to increased costs for storage of stem cells.
BACKGROUND:Plerixafor (Mozobil, AMD3100) with granulocyte-colony stimulating factor (G-CSF) mobilizes more CD34+ cells/kg compared to G-CSF alone. Given that plerixafor enhances mobilization of multiple white blood cell lineages, we determined if more storage space is required for products collected from patients mobilized with plerixafor. METHODS: A review of the medical records of 15 patients mobilized with chemotherapy and G-CSF (control) and 14 patients mobilized with plerixafor plus G-CSF (plerixafor) was performed. Data on demographics, baseline characteristics, CD34+ cells/kg, total nucleated cells, total mononuclear cells, total apheresis sessions, and total bags for storage were collected. Mean values were determined and compared using Student's t-test. RESULTS: We found that the proportion of CD34+ cells among total nucleated cells was less in the plerixafor group compared to the control group (P = 0.0427). More nucleated cells (10.7 x 10(10) vs. 7.1 x 10(10), P =0.0452) and mononuclear cells (9.7 x 10(10) vs. 5.9 x 10(10), P = 0.0059) were mobilized with plerixafor plus G-CSF. However, there was no significant difference in CD34+ cells/kg, total CD34+ cells or the proportion of mononuclear cells among total nucleated cells between the two groups. More storage bags were required for the plerixafor group compared to the control group (15 vs. 9, P = 0.0299). CONCLUSION: Mobilization with plerixafor plus G-CSF resulted in a smaller proportion of CD34+ cells collected and a greater number of storage bags. An increase in the number of bags required for stem cell storage may be logistically problematic and will also lead to increased costs for storage of stem cells.
Authors: S Limat; M C Woronoff-Lemsi; N Milpied; I Chartrin; N Ifrah; E Deconinck; R Gressin; P Colombat; J Y Cahn; P Arveux Journal: Eur J Cancer Date: 2000-12 Impact factor: 9.162
Authors: Robert E Donahue; Ping Jin; Aylin C Bonifacino; Mark E Metzger; Jiaqiang Ren; Ena Wang; David F Stroncek Journal: Blood Date: 2009-07-14 Impact factor: 22.113
Authors: C J Fowler; A Dunn; B Hayes-Lattin; K Hansen; L Hansen; K Lanier; V Nelson; T Kovacsovics; J Leis; G Calandra; R T Maziarz Journal: Bone Marrow Transplant Date: 2009-02-02 Impact factor: 5.483
Authors: Stefan Fruehauf; Marlon Romano Veldwijk; Timon Seeger; Mario Schubert; Stephanie Laufs; Julian Topaly; Patrick Wuchter; Falk Dillmann; Volker Eckstein; Frederik Wenz; Hartmut Goldschmidt; Anthony Dick Ho; Gary Calandra Journal: Cytotherapy Date: 2009 Impact factor: 5.414
Authors: M J Dugan; R T Maziarz; W I Bensinger; A Nademanee; J Liesveld; K Badel; C Dehner; C Gibney; G Bridger; G Calandra Journal: Bone Marrow Transplant Date: 2009-06-01 Impact factor: 5.483
Authors: B J Bolwell; B Pohlman; L Rybicki; R Sobecks; R Dean; J Curtis; S Andresen; A Koo; V Mineff; M Kalaycio; J W Sweetenham Journal: Bone Marrow Transplant Date: 2007-07-09 Impact factor: 5.483
Authors: Patrick Stiff; Ivana Micallef; Philip McCarthy; Margarida Magalhaes-Silverman; Daniel Weisdorf; Mary Territo; Karin Badel; Gary Calandra Journal: Biol Blood Marrow Transplant Date: 2009-02 Impact factor: 5.742
Authors: John F DiPersio; Ivana N Micallef; Patrick J Stiff; Brian J Bolwell; Richard T Maziarz; Eric Jacobsen; Auayporn Nademanee; John McCarty; Gary Bridger; Gary Calandra Journal: J Clin Oncol Date: 2009-08-31 Impact factor: 44.544
Authors: R E Clark; J Bell; J O Clark; B Braithwaite; U Vithanarachchi; N McGinnity; T Callaghan; S Francis; R Salim Journal: Blood Cancer J Date: 2014-10-31 Impact factor: 11.037